Ossianix
Stevenage Bioscience Catalyst
Gunnels Wood Road
Stevenage
Hertfordshire
SG12FX
United Kingdom
Tel: 44-0-1438906821
Fax: 44-0-7931951118
Website: http://ossianix.com/
About Ossianix
OSSIANIX, INC is a privately held pre clinical company that develops Biotherapeutic products using the highly versatile single domain VNAR antibody from the shark. The attractive biological and biophysical properties of the VNAR structure allows the rapid delivery of exquisitely high-affinity products to multiple target classes that have proven difficult or impossible by standard antibody approaches or alternative scaffolds.YEAR FOUNDED:
2011
LEADERSHIP:
Founder and CEO: Frank S Walsh
Founder and CSO: J Lynn Rutkowski
Co-Founder: Corey Goodman
COO: Steve Moore
5 articles about Ossianix
-
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
11/17/2022
Attralus, Inc. and Ossianix announced today that they have entered into a definitive agreement using Ossianix' brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s Disease.
-
CORRECTION: Ossianix Announces Publication of Positive Preclinical Data on Neutralizing SARS-CoV-2 Infection with a Panel of Single Domain Shark VNAR Antibodies
6/10/2021
Ossianix, an antibody engineering company, and the University of Graz announced the publication of a preclinical study that describes discovery of highly potent neutralizing single domain shark antibodies directed against the SARS-CoV-2 spike protein.
-
Ossianix to Present Preclinical Data Demonstrating Best-in-Class Blood Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodies
11/9/2020
Ossianix, an antibody engineering company, announced the results of a non-human primate study demonstrating best-in-class blood-brain barrier delivery by single domain antibodies.
-
Ossianix and Novo Nordisk Sign Research and Option Agreement on Blood Brain Barrier Delivery Technology for Proteins in Diabetes and Other Metabolic Diseases
9/4/2018
Ossianix, Inc. today announced a research collaboration and option agreement with Novo Nordisk to deliver therapeutic molecules in diabetes and other metabolic diseases across the Blood Brain Barrier (BBB) to the brain.
-
Ossianix Release: Company Receives Milestone Payment From H. Lundbeck A/S For Blood-Brain Barrier (BBB) Antibody Delivery Technology
1/26/2017